Skip to Content

Fycompa Approval History

  • FDA approved: Yes (First approved October 22nd, 2012)
  • Brand name: Fycompa
  • Generic name: perampanel
  • Dosage form: Tablets and Oral Suspension
  • Company: Eisai Inc.
  • Treatment for: Epilepsy, Seizures

Fycompa (perampanel) is a non-competitive AMPA glutamate receptor antagonist indicated for the treatment of partial-onset seizures, and as adjunctive therapy in the treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy.

Development History and FDA Approval Process for Fycompa

Jul 27, 2017Approval FDA Approves Additional Use of Antiepileptic Drug Fycompa as Monotherapy for Partial-onset Seizures
May  2, 2016Approval Eisai Announces FDA Approval of Fycompa (perampanel) Oral Suspension
Jun 22, 2015Approval FDA Approves Fycompa as Adjunctive Treatment for Primary Generalized Tonic-Clonic Seizures
Oct 22, 2012Approval FDA Approves Fycompa to Treat Seizures
Mar  5, 2012FDA Accepts Resubmission of Perampanel New Drug Application
Dec 26, 2011Eisai Resubmits Perampanel (E2007) NDA to FDA
Jul 29, 2011U.S. FDA Provides Response to Perampanel New Drug Application
Jan 25, 2011Eisai to Submit Marketing Authorization Applications in the U.S. and EU for Perampanel as Adjunctive Therapy for Partial Onset SeizuresĀ in Patients with Epilepsy

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.